Neurotech Night @ MIT Enterprise Forum Nov 12th

On Wednesday, November 12th 6:00p to 8:30p in the MIT Stata Center's Kirsch Auditorium, the MIT Enterprise Forum Innovation Series presents:

Neuroscience Drug Discovery and Development: The Route to Disease-Modifying Therapies

This all-star keynote plus live-case study plus panel discussion will survey the economically enormous health sector covering disorders of the brain, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease and psychiatric diseases such as schizophrenia and depression, pose some of the hardest challenges for the biopharmaceutical industry. See how biopharma ventures are addressing these challenges, with guest speakers from the cutting edge of neuroscience drug discovery, including:

• Keynote: Darryle D. Schoepp, Ph.D., Senior Vice President and Neuroscience Franchise Head, Merck Research Laboratories, PA. Dr. Schoepp is responsible for the scientific direction of drug discovery and development for neuroscience programs at Merck. Prior to joining Merck he was a VP at Eli Lilly, where he led the development of a new first-in-class drug for the treatment of schizophrenia.
• Company Presentation: Christoph M. Adams, Ph.D., Chief Business Officer, FoldRx Pharmaecuticals, Inc. FoldRx was co-founded by Susan Lindquist, Professor of Biology at MIT, former Director of Whitehead Institute
  
• Panelist: Robert Desimone, Ph.D., Director, McGovern Institute for Brain Research at MIT
• Panelist: Douglas M. Fambrough, Ph.D., General Partner, Oxford Bioscience Partners
• Panelist: Todd Sherer, Ph.D., Vice President Research Programs, The Michael J. Fox Foundation for Parkinson’s Research
• Moderator: Skip Irving, Partner and Managing Director, Health Advances LLC

More info (and sponsor, partner, and presenter bio details) on the MIT Enterprise Forum website. Students free with ID. Everyone should pre-register! This is a not-to-be-missed session on neurotechnology ventures!